Basecamp Research Raises $140M to Advance Six AI-Designed Therapy Programs

Basecamp Research has raised $140 million and disclosed a six-program pipeline for therapies designed with AI. Its first focus is reprogramming patients’ cells inside the body, while its reported results remain preclinical.

S32 led the oversubscribed Series C, joined by NVIDIA and Anthropic’s Anthology Fund. Basecamp plans to use the funding to train a new generation of its EDEN biological models and advance its therapies toward clinical development.

Endpoints News describes the six-program pipeline as a test of Basecamp’s AI. The company says it has preclinical results across multiple treatment approaches and disease areas, but has not detailed results for each of the six programs. That limits how closely the individual programs can be assessed.

How the proposed therapy would work

Basecamp says its proprietary Trillion Gene Atlas draws on biological-data partnerships in more than 30 countries. The dataset trains EDEN to recognize patterns in biology. For its proposed cell therapies, Basecamp aims to pair long DNA sequences designed with EDEN with enzymes called serine recombinases, which can insert those sequences into a cell’s genome.

In vivo means the changes would happen inside a patient’s body, rather than requiring cells to be modified outside it and then administered. Basecamp wants that method to support more sophisticated and customizable cell therapies. Those are goals for the platform, not established patient benefits.

What the lab work has shown

In January, Basecamp introduced EDEN models for programmable gene insertion. It said it had demonstrated insertion at more than 10,000 disease-related locations in the human genome. It also reported that engineered cancer-fighting cells cleared more than 90% of tumor cells in laboratory assays. Those figures describe experiments, not outcomes in patients.

The earlier work extended beyond gene insertion. Basecamp reported confirmed laboratory activity for 97% of the EDEN-assisted antimicrobial peptide candidates it tested. Peptides are small proteins; that result shows another type of design the company is exploring, rather than progress for a named program in the new pipeline.

From models toward medicines

Basecamp has appointed former Biogen executive Richard Pearce as chief business officer to expand pharmaceutical partnerships. S32 general partner Andy Conrad is joining its board. The financing and appointments give the company resources for development, but its stated next step remains moving the therapies toward clinical work.